Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective

References

1. Bucher, D., Popple, S., Baer, M., Mikhail, A., Gong, Y. F., Whitaker, C., Paoletti, E. & Judd, A.(1989). M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol 63, 3622–3633. [Google Scholar]
2. Darnule, T. V., Likhite, V., Darnule, A. T., Turino, G. M. & Mandl, I.(1980). Enhancement of humoral immune response against human lung elastin peptides. Experientia 36, 606–607.[CrossRef] [Google Scholar]
3. Dawood, F. S., Jain, S., Finelli, L., Shaw, M. W., Lindstrom, S., Garten, R. J., Gubareva, L. V., Xu, X., Bridges, C. B. & Uyeki, T. M.(2009). Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360, 2605–2615.[CrossRef] [Google Scholar]
4. De Filette, M., Min Jou, W., Birkett, A., Lyons, K., Schultz, B., Tonkyro, A., Resch, S. & Fiers, W.(2005). Universal influenza A vaccine: optimization of M2-based constructs. Virology 337, 149–161.[CrossRef] [Google Scholar]
5. Fiore, A. E., Bridges, C. B. & Cox, N. J.(2009). Seasonal influenza vaccines. Curr Top Microbiol Immunol 333, 43–82. [Google Scholar]
6. Grebe, K. M., Yewdell, J. W. & Bennink, J. R.(2008). Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10, 1024–1029.[CrossRef] [Google Scholar]
7. Hanly, W. C., Artwohl, J. E. & Bennett, B. T.(1995). Review of polyclonal antibody production procedures in mammals and poultry. ILAR J 37, 93–118.[CrossRef] [Google Scholar]
8. Jegerlehner, A., Schmitz, N., Storni, T. & Bachmann, M. F.(2004). Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172, 5598–5605.[CrossRef] [Google Scholar]
9. Lamb, R. A., Zebedee, S. L. & Richardson, C. D.(1985). Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40, 627–633.[CrossRef] [Google Scholar]
10. Mera, K., Nagai, M., Brock, J. W., Fujiwara, Y., Murata, T., Maruyama, T., Baynes, J. W., Otagiri, M. & Nagai, R.(2008). Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products. J Immunol Methods 334, 82–90.[CrossRef] [Google Scholar]
11. Mozdzanowska, K., Feng, J., Eid, M., Kragol, G., Cudic, M., Otvos, L., Jr & Gerhard, W.(2003). Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21, 2616–2626.[CrossRef] [Google Scholar]
12. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. & Fiers, W.(1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5, 1157–1163.[CrossRef] [Google Scholar]
13. Pinto, L. H., Holsinger, L. J. & Lamb, R. A.(1992). Influenza virus M2 protein has ion channel activity. Cell 69, 517–528.[CrossRef] [Google Scholar]
14. Reed, L. J. & Muench, H.(1938). A simple method for estimating fifty percent endpoints. Am J Hyg 27, 493–497. [Google Scholar]
15. Schulze, I. T.(1970). The structure of influenza virus. I. The polypeptides of the virion. Virology 42, 890–904.[CrossRef] [Google Scholar]
16. Wang, R., Song, A., Levin, J., Dennis, D., Zhang, N. J., Yoshida, H., Koriazova, L., Madura, L., Shapiro, L. & other authors(2008). Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80, 168–177.[CrossRef] [Google Scholar]
17. Webster, R. G. & Hinshaw, V. S.(1977). Matrix protein from influenza A virus and its role in cross-protection in mice. Infect Immun 17, 561–566. [Google Scholar]
18. Zebedee, S. L. & Lamb, R. A.(1989). Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. Proc Natl Acad Sci U S A 86, 1061–1065.[CrossRef] [Google Scholar]